These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23974193)

  • 1. Pomalidomide.
    Lacy MQ; McCurdy AR
    Blood; 2013 Oct; 122(14):2305-9. PubMed ID: 23974193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pomalidomide for multiple myeloma.
    Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
    Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
    Roziaková L; Mistrík M; Bátorová A
    Klin Onkol; 2014; 27(5):318-25. PubMed ID: 25312708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pomalidomide for multiple myeloma].
    Fouquet G; Macro M; Decaux O; Fohrer C; Guidez S; Demarquette H; Le Grand C; Prodhomme C; Renaud L; Bories C; Herbaux C; Karlin L; Roussel M; Benboubker L; Hulin C; Arnulf B; Leleu X
    Rev Med Interne; 2015 Sep; 36(9):613-8. PubMed ID: 26257103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
    Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
    Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of pomalidomide therapy in multiple myeloma: a recent survey.
    Kumar A; Porwal M; Verma A; Mishra AK
    J Chemother; 2014 Dec; 26(6):321-7. PubMed ID: 25004945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pomalidomide for multiple myeloma].
    Dougé A; Lemal R; Chaleteix C
    Bull Cancer; 2017 Sep; 104(9):707-713. PubMed ID: 28583668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
    Richardson PG; Mark TM; Lacy MQ
    Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S36-44. PubMed ID: 23786844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pomalidomide for the management of refractory multiple myeloma.
    Summers BB; Cole SW; Olin JL
    Am J Health Syst Pharm; 2014 Sep; 71(17):1443-8. PubMed ID: 25147167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
    Lacy MQ; Tefferi A
    Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pomalidomide in the treatment of relapsed multiple myeloma.
    Forsberg PA; Mark TM
    Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.
    Holstein SA; McCarthy PL
    Drugs; 2017 Apr; 77(5):505-520. PubMed ID: 28205024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide in multiple myeloma.
    Kim Y; Schmidt-Wolf IG
    Expert Rev Anticancer Ther; 2015 May; 15(5):491-7. PubMed ID: 25843431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pomalidomide for patients with multiple myeloma.
    Gras J
    Drugs Today (Barc); 2013 Sep; 49(9):555-62. PubMed ID: 24086951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory compounds (IMiDs) in the treatment of multiple myeloma.
    Srkalovic G; Hussein M
    Bosn J Basic Med Sci; 2009 Oct; 9 Suppl 1(Suppl 1):S3-S10. PubMed ID: 19912117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel immunomodulatory compounds in multiple myeloma.
    Saini N; Mahindra A
    Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pomalidomide in the management of relapsed multiple myeloma.
    Touzeau C; Moreau P
    Future Oncol; 2016 Sep; 12(17):1975-83. PubMed ID: 27283457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
    Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
    Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pomalidomide (Pomalyst) for multiple myeloma.
    Med Lett Drugs Ther; 2015 Apr; 57(1467):e66-7. PubMed ID: 25988965
    [No Abstract]   [Full Text] [Related]  

  • 20. Carfilzomib.
    Kortuem KM; Stewart AK
    Blood; 2013 Feb; 121(6):893-7. PubMed ID: 23393020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.